Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?

Artificial Organs

Volumn 38, Issue 2, 2014, Pages 135-141

  Rosada, Adrian ^a   Kassner, Ursula ^a   Vogt, Anja ^a   Willhauck, Michael ^a   Parhofer, Klaus ^a   Steinhagen Thiessen, Elisabeth ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cardiovascular events; Event free survival; Lipid apheresis; Lipoprotein(a)

Indexed keywords

CHOLESTEROL; DISEASES; LIPOPROTEINS; PATIENT MONITORING;

CARDIOVASCULAR EVENT; CONFIDENCE INTERVAL; EVENT-FREE SURVIVAL; LIPID APHERESIS; LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN(A); LOW DENSITY LIPOPROTEINS; RETROSPECTIVE ANALYSIS; RISK FACTORS; TIME-PERIODS;

PATIENT TREATMENT;

CARDIOVASCULAR AGENT; HEMOGLOBIN A1C; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; APHERESIS; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CORONARY ARTERY BYPASS SURGERY; CORONARY STENT; ENDARTERECTOMY; EVENT FREE SURVIVAL; FEMALE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; INCIDENCE; LABORATORY TEST; LIPID APHERESIS; LIPID BLOOD LEVEL; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SURVIVAL RATE;

CARDIOVASCULAR EVENTS; EVENT-FREE SURVIVAL; LIPID APHERESIS; LIPOPROTEIN(A);

AGED; BLOOD COMPONENT REMOVAL; CARDIOVASCULAR DISEASES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84894257728     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/aor.12135     Document Type: Article

References (27)

1. Berk K. A new serum type system in man-the Lp system. Acta Pathol Microbiol Scand 1963;59:369-382.
2. Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 1998;82:57U-66U.
3. Gaw A, Brown EA, Ford I. Impact of apo(a) length polymorphism and the control of plasma Lp(a) concentrations: evidence for a threshold effect. Arterioscler Thromb Vasc Biol 1998;18:1870-1876.
4. Nielsen LB, Gronholdt ML, Schroeder TV, Stender S, Nordestgaard BG. In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima. Arterioscler Thromb Vasc Biol 1997;17:905-911.
5. Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989;9:579-592.
6. Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem 2004;37:333-343.
7. Cremer P, Nagel D, Mann H, etal. Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis 1997;129:221-230.
8. Hoff HF, Beck GJ, Skibinski CI, etal. Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. Circulation 1988;77:1238-1244.
9. Nordestgaard BG, Chapman MJ, Ray K, etal. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31:2844-2853.
10. Matsunaga A, Handa K, Mori T, etal. Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia. Atherosclerosis 1992;94:241-248.
11. Seed M, O'Connor B, Perombelon N, O'Donnell M, Reaveley D, Knight BL. The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. Atherosclerosis 1993;101:61-68.
12. Pedersen TR, Kjekshus J, Berg K, etal. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995;345:1274-1275.
13. Banyai S, Streicher J, Strobl W, etal. Therapeutic efficiency of lipoprotein(a) reduction by low-density lipoprotein immunoapheresis. Metabolism 1998;47:1058-1064.
14. Armstrong VW, Schleef J, Thiery J, etal. Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the post-treatment return to baseline levels. Eur J Clin Invest 1989;19:235-240.
15. Julius U, Metzler W, Pietzsch J, Fassbender T, Klingel R. Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP. Int J Artif Organs 2002;25:1180-1188.
16. Richter WO, Donner MG, Schwandt P. Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation. Ther Apher 1999;3:203-208.
17. Kroon AA, van't Hof MA, Demacker PN, Stalenhoef AF. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis 2000;152:519-526.
18. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J. Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular diseases. Eur Heart J 2007;28:88-136.
19. Kassenärztliche Vereinigung Berlin. Qualitätsbericht 2011 der Kassenärztlichen Vereinigung Berlin Langfassung für das Berichtsjahr 2010. Qualitätsbericht, 2011.
20. Apstein CS, Zilversmit DB, Lees RS, George PK. Effect of intensive plasmapheresis on the plasma cholesterol concentration with familial hypercholesterolemia. Atherosclerosis 1978;31:105-115.
21. Jaeger BR, Richter Y, Nagel D, etal. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009;6:229-239.
22. Bohl S, Kassner U, Eckardt R, etal. Single lipoprotein apheresis session improves cardiac microvascular function in patients with elevated lipoprotein(a): detection by stress/rest perfusion magnetic resonance imaging. Ther Apher Dial 2009;13:129-137.
23. Daida H, Lee YJ, Yokoi H, etal. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis. Low-Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group. Am J Cardiol 1994;73:1037-1040.
24. Koizumi J, Koizumi I, Uno Y, etal. Reduction of lipoprotein(a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia. Atherosclerosis 1993;100:65-74.
25. Saal SD, Parker TS, Gordon BR, etal. Removal of low-density lipoproteins in patients by extracorporeal immunoadsorption. Am J Med 1986;80:583-589.
26. Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1975;1:1208-1211.
27. Parhofer KG, Vogt A. Mipomersen an apoB synthesis inhibitor evaluation of potential to reduce necessity for lipid-apheresis in patients with heterozygous FH and CAD. Atheroscler Suppl 2011;12:159.